Dave H.
About Dave H.
Dave H. serves as the Chief Scientific Officer at Exscientia, where he has worked since 2020. With over 25 years of experience in the pharmaceutical and biotech sectors, he specializes in medicinal chemistry and integrates AI technologies in drug discovery.
Work at Exscientia
Dave H. has served as the Chief Scientific Officer at Exscientia since 2020. In this role, he operates in a hybrid work environment based in Oxford, United Kingdom. His responsibilities include overseeing scientific initiatives and integrating advanced technologies into drug discovery processes. Under his leadership, Exscientia focuses on leveraging artificial intelligence and automation to enhance medicinal chemistry and therapeutic development.
Education and Expertise
Dave H. holds a Bachelor of Arts degree in Natural Sciences from the University of Cambridge, where he studied from 1989 to 1992. He furthered his education with a PhD in Synthetic Organic Chemistry from The University of Manchester, completed between 1992 and 1995. He also completed a Postdoctoral fellowship in Synthetic Organic Chemistry at The University of Texas at Austin in 1996. With over 25 years of experience in the pharmaceutical and biotech sectors, he specializes in medicinal chemistry, particularly in neuroscience and pain therapeutic areas.
Background
Dave H. has a diverse professional background, having worked at several prominent organizations in the pharmaceutical industry. He spent nine years as a Research Fellow at Merck from 1996 to 2005, followed by an eleven-year tenure at Evotec, where he held the position of Executive Vice President of Chemistry from 2005 to 2016. He then transitioned to the role of Executive Vice President of Alliance Management at Evotec from 2016 to 2019. This extensive experience has contributed to his expertise in drug discovery and development.
Achievements
Throughout his career, Dave H. has made significant contributions to the fields of medicinal chemistry and drug discovery. He has integrated innovative technologies such as AI generative design and automation into his work processes. Additionally, he applies induced pluripotent stem cells (iPSCs) in drug discovery and explores protein degradation therapeutic modalities. His work has focused on the discovery and early development of small molecules, enhancing therapeutic options in various medical fields.